Literature DB >> 26454021

Activation of cerebral sodium-glucose transporter type 1 function mediated by post-ischemic hyperglycemia exacerbates the development of cerebral ischemia.

Y Yamazaki1, S Ogihara1, S Harada1, S Tokuyama2.   

Abstract

The regulation of post-ischemic hyperglycemia plays an important role in suppressing neuronal damage in therapeutic strategies for cerebral ischemia. We previously reported that the cerebral sodium-glucose transporter (SGLT) was involved in the post-ischemic hyperglycemia-induced exacerbation of cerebral ischemic neuronal damage. Cortical SGLT-1, one of the cerebral SGLT isoforms, is dramatically increased by focal cerebral ischemia. In this study, we focused on the involvement of cerebral SGLT-1 in the development of cerebral ischemic neuronal damage. It was previously reported that activation of 5'-adenosine monophosphate-activated protein kinase (AMPK) increases SGLT-1 expression. Moreover, ischemic stress-induced activation of AMPK exacerbates cerebral ischemic neuronal damage. Therefore, we directly confirmed the relationship between cerebral SGLT-1 and cerebral AMPK activation using in vitro primary culture of mouse cortical neurons. An in vivo mouse model of focal cerebral ischemia was generated using a middle cerebral artery occlusion (MCAO). The development of infarct volume and behavioral abnormalities on day 3 after MCAO were ameliorated in cerebral SGLT-1 knock down mice. Cortical and striatal SGLT-1 expression levels were significantly increased at 12h after MCAO. Immunofluorescence revealed that SGLT-1 and the neuronal nuclear antigen (NeuN) were co-localized in the cortex and striatum of MCAO mice. In the in vitro study, primary cortical neurons were cultured for five days before each treatment with reagents. Concomitant treatment with hydrogen peroxide and glucose induced the elevation of SGLT-1 and phosphorylated AMPK/AMPK ratio, and this elevation was suppressed by compound C, an AMPK inhibitor in primary cortical neurons. Moreover, compound C suppressed neuronal cell death induced by concomitant hydrogen peroxide/glucose treatment in primary cortical neurons. Therefore, we concluded that enhanced cerebral SGLT-1 function mediated by post-ischemic hyperglycemia exacerbates the development of cerebral ischemic neuronal damage. One of the mechanisms of cerebral SGLT-1 up-regulation may be involved in the AMPK activation after cerebral ischemia.
Copyright © 2015 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  5′-adenosine monophosphate-activated protein kinase; cerebral ischemia; glucose transporter; hyperglycemia; sodium-glucose transporter type 1

Mesh:

Substances:

Year:  2015        PMID: 26454021     DOI: 10.1016/j.neuroscience.2015.10.005

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  10 in total

Review 1.  Glucose transporters in brain in health and disease.

Authors:  Hermann Koepsell
Journal:  Pflugers Arch       Date:  2020-08-13       Impact factor: 3.657

2.  Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy.

Authors:  Mumin Alper Erdogan; Dimas Yusuf; Joanna Christy; Volkan Solmaz; Arife Erdogan; Emin Taskiran; Oytun Erbas
Journal:  BMC Neurol       Date:  2018-06-07       Impact factor: 2.474

Review 3.  The role of KATP channels in cerebral ischemic stroke and diabetes.

Authors:  Vivian Szeto; Nai-Hong Chen; Hong-Shuo Sun; Zhong-Ping Feng
Journal:  Acta Pharmacol Sin       Date:  2018-04-19       Impact factor: 6.150

4.  Expression profiling and immunolocalization of Na+-D-glucose-cotransporter 1 in mice employing knockout mice as specificity control indicate novel locations and differences between mice and rats.

Authors:  Ivana Vrhovac Madunić; Davorka Breljak; Dean Karaica; Hermann Koepsell; Ivan Sabolić
Journal:  Pflugers Arch       Date:  2017-08-26       Impact factor: 3.657

Review 5.  The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus.

Authors:  Bertram Pitt; Gabriel Steg; Lawrence A Leiter; Deepak L Bhatt
Journal:  Cardiovasc Drugs Ther       Date:  2021-11-09       Impact factor: 3.947

6.  Ginsenoside Rd protects cerebral endothelial cells from oxygen-glucose deprivation/reoxygenation induced pyroptosis via inhibiting SLC5A1 mediated sodium influx.

Authors:  Suping Li; Nengwei Yu; Fei Xu; Liang Yu; Qian Yu; Jing Fu
Journal:  J Ginseng Res       Date:  2022-05-21       Impact factor: 5.735

7.  Reply to letter to editor regarding the article, "Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy".

Authors:  D Dutta; S Kalra; M Sharma
Journal:  J Postgrad Med       Date:  2017 Oct-Dec       Impact factor: 1.476

Review 8.  Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy.

Authors:  D Dutta; S Kalra; M Sharma
Journal:  J Postgrad Med       Date:  2017 Apr-Jun       Impact factor: 1.476

9.  Exosomes from miRNA-126-modified endothelial progenitor cells alleviate brain injury and promote functional recovery after stroke.

Authors:  Jinju Wang; Shuzhen Chen; Wenfeng Zhang; Yanfang Chen; Ji C Bihl
Journal:  CNS Neurosci Ther       Date:  2020-10-03       Impact factor: 5.243

10.  Mizagliflozin, a selective SGLT1 inhibitor, improves vascular cognitive impairment in a mouse model of small vessel disease.

Authors:  Nanae Ishida; Maki Saito; Sachiko Sato; Yu Tezuka; Atsushi Sanbe; Eiichi Taira; Masamichi Hirose
Journal:  Pharmacol Res Perspect       Date:  2021-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.